^
Association details:
| Biomarker: | IL6 elevation |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The impact of baseline peripheral cytokines on survival in metastatic clear cell renal cell carcinoma (RCC) treated with nivolumab: NIVOREN GETUG-AFU 26 Translational study.
Published date:
02/14/2022
Excerpt:
Increased levels of IL-6 (75th percentile=P75), IL-7 (P75), IL-8 (P50) and VEGF (P50) were significantly negatively associated with survival (IL-6: HR=2.44, p=0.0112; IL-7: HR=2.38, p=0.0123; IL-8: HR=2.80, p=0.0045, and VEGF: HR=2.43, p=0.0133). 4-1BB (P50) was associated with improved OS (HR=0.39, p=0.0375). Higher levels of IL-8 (P50) and VEGF (P50) were associated with worse PFS (IL-8: HR=2.50, p=0.0133, and VEGF: HR=1.96, p=0.0132) and worse ORR (IL-8: p=0.013, and VEGF: p=0.044)....Higher baseline plasma levels of IL-6, IL-7, IL-8 and VEGF were significantly associated with worse survival outcomes in mRCC pts treated with nivolumab within TRAINING cohort of the NIVOREN trial. In contrast, 4-1BB was significantly associated with improved OS. IL-8 and VEGF were also associated with worse PFS and ORR.
DOI:
10.1200/JCO.2022.40.6_suppl.379
Source:
Title:
687P - NIVOREN GETUG-AFU 26 translational study: Baseline peripheral cytokines predict survival in metastatic clear cell renal carcinoma (RCC) treated with nivolumab
Published date:
09/13/2021
Excerpt:
Increased levels of IL-6, BCA and BAFF were significantly negatively associated with survival (IL-6: HR=4.41, 95%CI: 1.26-15.43, p=0.0112; BCA: HR=4.74, 95%CI: 1.35-16.64, p=0.0076, and BAFF: HR=4.39, 95%CI:1.26-15.32, p=0.0114)...Higher baseline plasma levels of IL-6, BCA and BAFF were significantly associated with worse survival outcomes in mRCC pts treated with nivolumab within an exploratory cohort of NIVOREN trial.
Trial ID:
